The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels: The Regression Growth Evaluation Statin Study (REGRESS)
Abstract
Background Intensive lowering of serum cholesterol may retard progression of coronary atherosclerosis in selected groups of patients. However, few data are available on the potential benefit of serum cholesterol reduction in the broad range of patients with coronary atherosclerosis and normal to moderately elevated serum cholesterol levels who undergo various forms of treatment. The Regression Growth Evaluation Statin Study (REGRESS) addresses this group of patients. Methods and Results REGRESS is a double-blind, placebo-controlled multicenter study to assess the effects of 2 years of treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on progression and regression of coronary atherosclerosis in 885 male patients with a serum cholesterol level between 4 and 8 mmol/L (155 and 310 mg/dL) by quantitative coronary arteriography. Primary end points were (1) change in average mean segment diameter per patient and (2) change in average minimum obstruction diameter per patient. Clinical events were also analyzed. Of the 885 patients, 778 (88%) had an evaluable final angiogram. Mean segment diameter decreased 0.10 mm in the placebo group versus 0.06 mm in the pravastatin group ( P =.019): The mean difference between treatment groups was 0.04 mm, with a 95% CI of 0.01 to 0.07 mm. The median minimum obstruction diameter decreased 0.09 mm in the placebo group versus 0.03 mm in the pravastatin group ( P =.001): The difference of the medians between the treatment groups was 0.06 mm, with a CI of 0.02 to 0.08 mm. At the end of the follow-up period, 89% (CI, 86% to 92%) of the pravastatin patients and 81% (CI, 77% to 85%) of the placebo patients were without new cardiovascular events ( P =.002). Conclusions In symptomatic men with significant coronary atherosclerosis and normal to moderately elevated serum cholesterol, less progression of coronary atherosclerosis and fewer new cardiovascular events were observed in the group of patients treated with pravastatin than in the placebo group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Austen, W., Edwards, J., Frye, R., Gensini, G., Gott, V., Griffith, L., McGoon, D., Murphy, M., & Roe, B. (1975) · Circulation · doi:10.1161/01.cir.51.4.5 · Cited by 3,256
Quantitative Determination of Serum Triglycerides by the Use of Enzymes
Bucolo, G., & David, H. (1973) · Clinical Chemistry · doi:10.1093/clinchem/19.5.476 · Cited by 3,188
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.
Schuler, G., Hambrecht, R., Schlierf, G., Niebauer, J., Hauer, K., Neumann, J., Hoberg, E., Drinkmann, A., Bacher, F., & Grunze, M. (1992) · Circulation · doi:10.1161/01.cir.86.1.1 · Cited by 1,340
(1983) · Circulation · doi:10.1161/01.cir.68.5.939 · Cited by 1,199
Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.
Vita, J. A., Treasure, C. B., Nabel, E. G., McLenachan, J. M., Fish, R. D., Yeung, A. C., Vekshtein, V. I., Selwyn, A. P., & Ganz, P. (1990) · Circulation · doi:10.1161/01.cir.81.2.491 · Cited by 1,173
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Haskell, W. L., Alderman, E. L., Fair, J. M., Maron, D. J., Mackey, S. F., Superko, H. R., Williams, P. T., Johnstone, I. M., Champagne, M. A., & Krauss, R. M. (1994) · Circulation · doi:10.1161/01.cir.89.3.975 · Cited by 884
Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843
Kane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
Brensike, J. F., Levy, R. I., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., & Moriarty, D. J. (1984) · Circulation · doi:10.1161/01.cir.69.2.313 · Cited by 668
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 647
Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., Mack, W. J., Cashin-Hemphill, L., Hodis, H. N., DeBoer, L. W. V., Mahrer, P. R., Masteller, M. J., Vailas, L. I., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00002 · Cited by 637
Waters, D., Higginson, L., Gladstone, P., Kimball, B., Le May, M., Boccuzzi, S. J., & Lespérance, J. (1994) · Circulation · doi:10.1161/01.cir.89.3.959 · Cited by 499
Diet, Lipoproteins, and the Progression of Coronary Atherosclerosis: The Leiden Intervention Trial
Arntzenius, A. C., Kromhout, D., Barth, J. D., Reiber, J. H. C., Bruschke, A. V. G., Buis, B., van Gent, C. M., Kempen-Voogd, N., Strikwerda, S., & van der Velde, E. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121301 · Cited by 497
Self-citationMyers, G. L., Cooper, G. R., Winn, C. L., & Smith, S. J. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30645-0 · Cited by 404
Warnick, G. R., Nguyen, T., & Albers, A. A. (1985) · Clinical Chemistry · doi:10.1093/clinchem/31.2.217 · Cited by 303
Sacks, F. M., Pasternak, R. C., Gibson, C. M., Rosner, B., & Stone, P. H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90506-1 · Cited by 187
(1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90858-a · Cited by 182
Diet, Lipoproteins and the Progression of Coronary Atherosclerosis
Arntzenius, A. C. (1986) · Drugs · doi:10.2165/00003495-198600311-00011 · Cited by 146
Bruschke, A. V. G., Kramer, J. R., Bal, E. T., Haque, I. U., Detrano, R., & Goormastic, M. (1989) · American Heart Journal · doi:10.1016/0002-8703(89)90772-2 · Cited by 141
Self-citationQuantitative coronary arteriography: equipment and technical requirements
Reiber, J. H. C., van der Zwet, P. M. J., Land, C. D. V., Koning, G., van Meurs, B., Buis, B., & van Voorthuisen, A. E. (1993) · Developments in cardiovascular medicine · doi:10.1007/978-94-011-1854-5_5 · Cited by 82
Self-citationClinical-pathological correlations of coronary disease progression and regression.
Fuster, V., Badimón, J. J., & Badimón, L. (1992) · PubMed · Cited by 72
Pitt, B., Ellis, S. G., Mancini, G. B. J., Rosman, H., McGovern, M. E., & The PLAC I and PLAC II Investigators (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90214-w · Cited by 46
Cited by
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Intensive Lifestyle Changes for Reversal of Coronary Heart Disease
Ornish, D. (1998) · JAMA · doi:10.1001/jama.280.23.2001 · Cited by 1,730
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Metadata
- Authors
- Jukema, J. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H. C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J. M., van Rappard, F. M., & Lie, K. I.
- Venue
- Circulation
- Published
- 1995-05-15
- Volume
- 91
- Issue
- 10
- Pages
- 2528-2540
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2131275408
- Cited by
- 842
- References
- 28
- FWCI
- 74.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.